Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel Free IVF Stock Alerts

INVO Fertility (IVF) Competitors

INVO Fertility logo
$0.97 0.00 (0.00%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$0.94 -0.03 (-3.30%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

IVF vs. MGRX, BMGL, AIDX, BIAF, and GXAI

Should you buy INVO Fertility stock or one of its competitors? INVO Fertility's main competitors and comparable companies include Mangoceuticals (MGRX), Basel Medical Group (BMGL), 20/20 Biolabs (AIDX), bioAffinity Technologies (BIAF), and Gaxos.ai (GXAI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does INVO Fertility compare to Mangoceuticals?

INVO Fertility (NASDAQ:IVF) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

INVO Fertility has a net margin of -116.29% compared to Mangoceuticals' net margin of -4,794.60%. INVO Fertility's return on equity of -85.54% beat Mangoceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
INVO Fertility-116.29% -85.54% -31.05%
Mangoceuticals -4,794.60%-96.39%-89.60%

INVO Fertility currently has a consensus price target of $20.00, indicating a potential upside of 1,961.86%. Given INVO Fertility's stronger consensus rating and higher probable upside, equities analysts plainly believe INVO Fertility is more favorable than Mangoceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INVO Fertility
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50
Mangoceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, INVO Fertility had 2 more articles in the media than Mangoceuticals. MarketBeat recorded 2 mentions for INVO Fertility and 0 mentions for Mangoceuticals. INVO Fertility's average media sentiment score of 0.49 beat Mangoceuticals' score of 0.00 indicating that INVO Fertility is being referred to more favorably in the media.

Company Overall Sentiment
INVO Fertility Neutral
Mangoceuticals Neutral

Mangoceuticals has lower revenue, but higher earnings than INVO Fertility. Mangoceuticals is trading at a lower price-to-earnings ratio than INVO Fertility, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INVO Fertility$7.53M0.32-$25.13M-$33.83N/A
Mangoceuticals$460K22.32-$20.64M-$1.01N/A

12.0% of INVO Fertility shares are held by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are held by institutional investors. 0.4% of INVO Fertility shares are held by insiders. Comparatively, 16.0% of Mangoceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

INVO Fertility has a beta of 2.34, suggesting that its share price is 134% more volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.04, suggesting that its share price is 104% more volatile than the broader market.

Summary

INVO Fertility beats Mangoceuticals on 11 of the 16 factors compared between the two stocks.

How does INVO Fertility compare to Basel Medical Group?

INVO Fertility (NASDAQ:IVF) and Basel Medical Group (NASDAQ:BMGL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

12.0% of INVO Fertility shares are owned by institutional investors. 0.4% of INVO Fertility shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

INVO Fertility currently has a consensus target price of $20.00, indicating a potential upside of 1,961.86%. Given INVO Fertility's stronger consensus rating and higher possible upside, equities research analysts clearly believe INVO Fertility is more favorable than Basel Medical Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INVO Fertility
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50
Basel Medical Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Basel Medical Group has a net margin of 0.00% compared to INVO Fertility's net margin of -116.29%. Basel Medical Group's return on equity of 0.00% beat INVO Fertility's return on equity.

Company Net Margins Return on Equity Return on Assets
INVO Fertility-116.29% -85.54% -31.05%
Basel Medical Group N/A N/A N/A

Basel Medical Group has higher revenue and earnings than INVO Fertility.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INVO Fertility$7.53M0.32-$25.13M-$33.83N/A
Basel Medical Group$8.90M0.82-$9.50MN/AN/A

In the previous week, Basel Medical Group had 4 more articles in the media than INVO Fertility. MarketBeat recorded 6 mentions for Basel Medical Group and 2 mentions for INVO Fertility. INVO Fertility's average media sentiment score of 0.49 beat Basel Medical Group's score of 0.00 indicating that INVO Fertility is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
INVO Fertility
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Basel Medical Group
0 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

INVO Fertility has a beta of 2.34, suggesting that its share price is 134% more volatile than the broader market. Comparatively, Basel Medical Group has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market.

Summary

INVO Fertility and Basel Medical Group tied by winning 7 of the 14 factors compared between the two stocks.

How does INVO Fertility compare to 20/20 Biolabs?

INVO Fertility (NASDAQ:IVF) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

12.0% of INVO Fertility shares are owned by institutional investors. 0.4% of INVO Fertility shares are owned by company insiders. Comparatively, 29.8% of 20/20 Biolabs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

20/20 Biolabs has a net margin of 0.00% compared to INVO Fertility's net margin of -116.29%. 20/20 Biolabs' return on equity of 0.00% beat INVO Fertility's return on equity.

Company Net Margins Return on Equity Return on Assets
INVO Fertility-116.29% -85.54% -31.05%
20/20 Biolabs N/A N/A N/A

20/20 Biolabs has lower revenue, but higher earnings than INVO Fertility. 20/20 Biolabs is trading at a lower price-to-earnings ratio than INVO Fertility, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INVO Fertility$7.53M0.32-$25.13M-$33.83N/A
20/20 Biolabs$2.05M2.90-$3.74M-$0.54N/A

In the previous week, INVO Fertility and INVO Fertility both had 2 articles in the media. INVO Fertility's average media sentiment score of 0.49 beat 20/20 Biolabs' score of 0.00 indicating that INVO Fertility is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
INVO Fertility
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
20/20 Biolabs
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

INVO Fertility presently has a consensus price target of $20.00, indicating a potential upside of 1,961.86%. 20/20 Biolabs has a consensus price target of $5.00, indicating a potential upside of 975.04%. Given INVO Fertility's stronger consensus rating and higher probable upside, research analysts plainly believe INVO Fertility is more favorable than 20/20 Biolabs.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INVO Fertility
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50
20/20 Biolabs
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

20/20 Biolabs beats INVO Fertility on 8 of the 15 factors compared between the two stocks.

How does INVO Fertility compare to bioAffinity Technologies?

bioAffinity Technologies (NASDAQ:BIAF) and INVO Fertility (NASDAQ:IVF) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

In the previous week, bioAffinity Technologies had 3 more articles in the media than INVO Fertility. MarketBeat recorded 5 mentions for bioAffinity Technologies and 2 mentions for INVO Fertility. INVO Fertility's average media sentiment score of 0.49 beat bioAffinity Technologies' score of 0.15 indicating that INVO Fertility is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
bioAffinity Technologies
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
INVO Fertility
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

INVO Fertility has a net margin of -116.29% compared to bioAffinity Technologies' net margin of -257.30%. INVO Fertility's return on equity of -85.54% beat bioAffinity Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
bioAffinity Technologies-257.30% -220.52% -136.76%
INVO Fertility -116.29%-85.54%-31.05%

INVO Fertility has a consensus target price of $20.00, indicating a potential upside of 1,961.86%. Given INVO Fertility's stronger consensus rating and higher probable upside, analysts clearly believe INVO Fertility is more favorable than bioAffinity Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
bioAffinity Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
INVO Fertility
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50

1.6% of bioAffinity Technologies shares are owned by institutional investors. Comparatively, 12.0% of INVO Fertility shares are owned by institutional investors. 2.7% of bioAffinity Technologies shares are owned by insiders. Comparatively, 0.4% of INVO Fertility shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

bioAffinity Technologies has higher earnings, but lower revenue than INVO Fertility. bioAffinity Technologies is trading at a lower price-to-earnings ratio than INVO Fertility, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bioAffinity Technologies$6.16M0.92-$14.91M-$109.45N/A
INVO Fertility$7.53M0.32-$25.13M-$33.83N/A

bioAffinity Technologies has a beta of -1.11, suggesting that its stock price is 211% less volatile than the broader market. Comparatively, INVO Fertility has a beta of 2.34, suggesting that its stock price is 134% more volatile than the broader market.

Summary

INVO Fertility beats bioAffinity Technologies on 12 of the 16 factors compared between the two stocks.

How does INVO Fertility compare to Gaxos.ai?

Gaxos.ai (NASDAQ:GXAI) and INVO Fertility (NASDAQ:IVF) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Gaxos.ai has a net margin of -64.81% compared to INVO Fertility's net margin of -116.29%. Gaxos.ai's return on equity of -38.79% beat INVO Fertility's return on equity.

Company Net Margins Return on Equity Return on Assets
Gaxos.ai-64.81% -38.79% -36.99%
INVO Fertility -116.29%-85.54%-31.05%

Gaxos.ai has higher earnings, but lower revenue than INVO Fertility. Gaxos.ai is trading at a lower price-to-earnings ratio than INVO Fertility, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gaxos.ai$6.01M1.07-$3.90M-$0.50N/A
INVO Fertility$7.53M0.32-$25.13M-$33.83N/A

42.6% of Gaxos.ai shares are held by institutional investors. Comparatively, 12.0% of INVO Fertility shares are held by institutional investors. 3.2% of Gaxos.ai shares are held by company insiders. Comparatively, 0.4% of INVO Fertility shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Gaxos.ai and Gaxos.ai both had 2 articles in the media. INVO Fertility's average media sentiment score of 0.49 beat Gaxos.ai's score of -0.36 indicating that INVO Fertility is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gaxos.ai
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
INVO Fertility
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

INVO Fertility has a consensus price target of $20.00, indicating a potential upside of 1,961.86%. Given INVO Fertility's stronger consensus rating and higher possible upside, analysts plainly believe INVO Fertility is more favorable than Gaxos.ai.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gaxos.ai
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
INVO Fertility
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50

Gaxos.ai has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, INVO Fertility has a beta of 2.34, indicating that its stock price is 134% more volatile than the broader market.

Summary

INVO Fertility beats Gaxos.ai on 8 of the 15 factors compared between the two stocks.

Get INVO Fertility News Delivered to You Automatically

Sign up to receive the latest news and ratings for IVF and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IVF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IVF vs. The Competition

Export
MetricINVO FertilityHealthcare Providers & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2.43M$9.76B$7.22B$12.94B
Dividend YieldN/A2.62%2.57%12.81%
P/E Ratio-0.0334.09275.5025.40
Price / Sales0.324.92644.4182.37
Price / CashN/A24.5828.1334.74
Price / Book0.285.3110.576.32
Net Income-$25.13M$313.45M$3.49B$358.20M
7 Day Performance1.99%0.58%-0.25%0.42%
1 Month Performance-8.49%-1.89%-2.69%-3.30%
1 Year Performance-97.25%16.29%18.16%5.33%

INVO Fertility Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IVF
INVO Fertility
1.8327 of 5 stars		$0.97
flat		$20.00
+1,961.9%		-97.2%$2.43M$7.53MN/A46
MGRX
Mangoceuticals
0.917 of 5 stars		$0.41
-0.2%		N/A-78.8%$8.84M$315.23KN/A3
BMGL
Basel Medical Group
0.4301 of 5 stars		$4.89
+2.2%		N/A-78.5%$7.65M$14.55MN/A36
AIDX
20/20 Biolabs
1.9981 of 5 stars		$0.58
-0.3%		$5.00
+768.1%		N/A$7.36M$2.05MN/A14
BIAF
bioAffinity Technologies
0.9225 of 5 stars		$10.48
+17.4%		N/A-87.4%$6.29M$6.16MN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:IVF) was last updated on 9/21/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel